SUNY DOWNSTATE MEDICAL CENTER
Tyrosine phosphorylation of p27Kip1 as a biomarker to identify Cdk4/6 inhibitor response
Tyrosine phosphorylation of p27Kip1 as a biomarker to identify Cdk4/6 inhibitor response is a funding opportunity from SUNY DOWNSTATE MEDICAL CENTER, up to 623507, closing November 30, 2026.
Nov 30, 2026
(122d left)Overview
SUMMARY While the CDK4 targeting drugs (CDK4i), Palbociclib, Abemaciclib, and Ribociclib, have shown clinical promise in the treatment of metastatic breast cancer (BC), lack of a companion diagnostic to identify responsive patients remains a problem. While CDK4i therapy increases progression-free survival (PFS) in…